Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin Dose
Top Cited Papers
- 2 June 2005
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (22) , 2285-2293
- https://doi.org/10.1056/nejmoa044503
Abstract
The management of warfarin therapy is complicated by a wide variation among patients in drug response. Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affect the response to warfarin.Keywords
This publication has 19 references indexed in Scilit:
- A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarinBlood, 2005
- Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature, 2004
- Identification of the gene for vitamin K epoxide reductaseNature, 2004
- Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarinThrombosis and Haemostasis, 2004
- A Comparison of Bayesian Methods for Haplotype Reconstruction from Population Genotype DataAmerican Journal of Human Genetics, 2003
- Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam MetabolismMolecular Pharmacology, 2002
- Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin TherapyJAMA, 2002
- A comprehensive review of genetic association studiesGenetics in Medicine, 2002
- Factors determining the maintenance dose of warfarin in Chinese patientsQJM: An International Journal of Medicine, 1996
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992